U.S. regulators need to release improved guidelines and provide financial incentives covering antibiotics development so researchers and companies will be encouraged to develop new drugs, particularly as cases of drug-resistant bacteria are increasing, experts on Wednesday told the House Committee on Energy and Commerce's Subcommittee on Health. "FDA plans to publish additional guidance on these [drug development] methods within the next six months to establish new standards for antimicrobial drugs," said Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research.

Full Story:

Related Summaries